Stop STALLING Act
- Bill Number
- S. 1095
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-04-10: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
- Last Updated
- 2025-09-03T19:44:20Z
Official Summary
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Sponsor
Cosponsors (6)
Sen. Grassley, Chuck [R-IA], Sen. Durbin, Richard J. [D-IL], Sen. Blumenthal, Richard [D-CT], Sen. Cruz, Ted [R-TX], Sen. Welch, Peter [D-VT], Sen. Booker, Cory A. [D-NJ]
Recent Actions
- 2025-04-10: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
- 2025-04-10: Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
- 2025-04-10: Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
- 2025-04-03: Committee on the Judiciary. Ordered to be reported without amendment favorably.
- 2025-03-24: Read twice and referred to the Committee on the Judiciary.
- 2025-03-24: Introduced in Senate
Bill Versions
- Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act — issued 2025-03-24 — PDF (7 pages)
- Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act — issued 2025-04-10 — PDF (8 pages)